Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
2/26/2026
China's Healthcare Reform Playbook: Boosting Births and Opening the Do...
2/25/2026
The Patent Term Compensation and Protection Scope in the Compensated P...
2/25/2026
Global Pharma Giants Rush to License Chinese Weight-Loss Drugs, Eye Ob...
2/25/2026
China Outpaces US and EU in Drug R&D with Faster Trials and Lower Cost...
2/25/2026
Henlius Expands Global Footprint with Exclusive Abbott Licensing Deal ...
2/25/2026
Slate Medicines Launches With $130M to Advance China-Licensed PACAP Mi...
2/25/2026
Prodegre Closes Angel+ Round to Advance CNS Pipeline and ATLAS™ Platf...
2/25/2026
Kelun-Biotech's sac-TMT OS Data Selected as Late-Breaker at ELCC 2026
2/25/2026
CDE Solicits Comments on Batch 104 of Chemical Generic Reference Formu...
2/25/2026
CASI Pharma to Be Delisted from Nasdaq, Shares to Move to OTC Market
2/25/2026
CStone Secures UK Approval for Sugemalimab in Stage III NSCLC
2/25/2026
China Schedules Antitrust Hearing in Abuse‑of‑Dominance Case Tied to...
2/24/2026
Pfizer Acquires China Rights to Sciwind's Approved GLP-1 Therapy
2/24/2026
United Labs and Novo Nordisk Post Strong Phase 2 Data for UBT251 Tripl...
2/24/2026
XtalPi and YolTech Forge AI Alliance to Advance mRNA and In Vivo CAR-T...
2/24/2026
Frontier Biotech Inks Global siRNA Licensing Deal with GSK
2/24/2026
Harbour BioMed Strikes $1.1B-Plus Ex-China Deal for Anti-CTLA-4 Antibo...
2/24/2026
Ascentage Registers U.S. Phase 1 Trial for BTK PROTAC APG-3288
2/24/2026
GenSci Advances PD-1 Agonist Into Phase 2b for Rheumatoid Arthritis
2/24/2026
Huadong Launches Head-to-Head Phase III Trial for Dual GLP-1/GIP Agoni...
2/24/2026
CDE Issues Guideline on Clinical Information for CAR-T Therapy Package...
2/24/2026
CDE Releases Q&A Document on Development Safety Update Reports
2/24/2026
CDE Issues Guidelines on Benefit-Risk Assessment Using Multi-Regional ...
2/24/2026
China Prepares to Implement Landmark Regulations for Clinical Research...
2/24/2026
Biokin's Iza-Bren Achieves Second Phase III Survival Success in China ...
2/24/2026
After 230% Deal Size Explosion, China Is No Longer the 'Bargain Baseme...
2/21/2026
Hansoh Pharma's Ameile Wins EU Approval for EGFR-Mutant Lung Cancer
2/21/2026
Leo Pharma Eyes China Comeback After Decade-Long Launch Drought
2/20/2026
CSPC's Long-Acting SYH2082 Clears FDA to Begin Clinical Trials
2/20/2026
China Biotech Kicks Off 2026 with $863 Million in January Raises
Page:
4
/
822
Total number of articles:
24634
:
[First]
[<<]
[2]
[3]
[4]
[5]
[6]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit